Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | ENO1 | P06733 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8440453 | 0.83 | ALDH1A1 (0.41) | PRKCAPOLBGAANPSR1ENO1 | |
| SCHEMBL12989425 | 0.78 | SIGMAR1 (0.42) | PRKCAPOLBGAANPSR1ENO1 | |
| SCHEMBL12422447 | 0.78 | SMN1; SMN2 (0.44) | POLBNPSR1 | |
| SCHEMBL7989600 | 0.73 | ENO1 (0.34) | PRKCAENO1 | |
| SCHEMBL7985517 | 0.73 | ENO1 (0.34) | PRKCAENO1 | |
| SCHEMBL12062146 | 0.71 | CHRM3 (0.38) | PRKCAPOLBGAANPSR1ENO1 | |
| SCHEMBL10102885 | 0.71 | ALDH1A1 (0.47) | POLBNPC1 | |
| SCHEMBL20161015 | 0.70 | — | — | |
| SCHEMBL12312757 | 0.69 | MAPK1 (0.40) | POLBGAA | |
| SCHEMBL24836106 | 0.68 | HSD17B10 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198304-B2 | Guanidine-containing compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-20110319448-A1 | GUANIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319448-A1 | GUANIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM1 | PRKCA 1090/4885POLB 3958/4885GAA 1568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.